DexCom, Inc. (DXCM)

NASDAQ: DXCM · Real-Time Price · USD
73.21
-2.12 (-2.81%)
Mar 25, 2025, 1:09 PM EDT - Market open
-2.81%
Market Cap 28.61B
Revenue (ttm) 4.03B
Net Income (ttm) 576.20M
Shares Out 390.77M
EPS (ttm) 1.42
PE Ratio 51.37
Forward PE 36.26
Dividend n/a
Ex-Dividend Date n/a
Volume 1,316,618
Open 75.24
Previous Close 75.32
Day's Range 72.88 - 75.93
52-Week Range 62.34 - 142.00
Beta 1.29
Analysts Strong Buy
Price Target 99.82 (+36.36%)
Earnings Date Apr 24, 2025

About DXCM

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time... [Read more]

Industry Medical Devices
Sector Healthcare
IPO Date Apr 14, 2005
Employees 10,300
Stock Exchange NASDAQ
Ticker Symbol DXCM
Full Company Profile

Financial Performance

In 2024, DexCom's revenue was $4.03 billion, an increase of 11.34% compared to the previous year's $3.62 billion. Earnings were $576.20 million, an increase of 6.41%.

Financial Statements

Analyst Forecast

According to 17 analysts, the average rating for DXCM stock is "Strong Buy." The 12-month stock price forecast is $99.82, which is an increase of 36.36% from the latest price.

Price Target
$99.82
(36.36% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Dexcom Report Unveiled at ATTD 2025 Reveals HCPs Favour Tech Over Medication for Future of Type 2 Care

EDINBURGH, Scotland & SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), a global leader in glucose biosensing, today announced the launch of its first multi-region report, the "Dexcom State of ...

6 days ago - Business Wire

History Says Shut Up And Buy: 12 Hyper-Growth Blue Chips To Buy Right Now

Market corrections, like the recent dip, are normal and temporary, with historical data showing average declines of 13-14% since 1950. Long-term investors should stay the course. Corrections often lea...

11 days ago - Seeking Alpha

Dexcom Appoints Renée Galá to Board of Directors

SAN DIEGO--(BUSINESS WIRE)--Dexcom Appoints Renée Galá to Board of Directors.

15 days ago - Business Wire

Dexcom receives FDA warning letter for two U.S. manufacturing facilities

Medical device maker Dexcom said it has received a warning letter from the U.S. Food and Drug Administration following inspections of its two key manufacturing facilities, sending its shares down near...

17 days ago - Reuters

DexCom Gets FDA Warning Letter After Inspections of Facilities

DexCom received a warning letter from the Food and Drug Administration following inspections of its San Diego and Mesa, Ariz. facilities and is working on a written response.

17 days ago - WSJ

DexCom, Inc. (DXCM) Presents at 46th Annual Raymond James Institutional Investors Brokers Conference (Transcript)

DexCom, Inc. (NASDAQ:DXCM) 46th Annual Raymond James Institutional Investors Conference March 4, 2025 10:25 AM ET Company Participants Jereme Sylvain - Chief Financial Officer Matt Carey - Manager of...

20 days ago - Seeking Alpha

Dexcom Announces Upcoming Conference Presentation

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the 46th Annual Raymond James Institutional Investors Conference on Tues...

26 days ago - Business Wire

Quality Key in Volatile Market, NFLX & DXCM Value Plays

Friday's trading session showed weakness is possible in the current market, and Lisa Schreiber says investors need to turn to quality in a time of volatility. Lisa expects the U.S. economy to bolster ...

Other symbols: NFLX
4 weeks ago - Schwab Network

Analyst Cautiously Optimistic On DexCom As Competitive Pressures Loom

On Thursday, Dexcom, Inc.'s DXCM fourth-quarter revenue rose 8% year-over-year to $1.114 billion, beating the analyst consensus estimate of $1.104 billion.

5 weeks ago - Benzinga

DexCom Analysts Increase Their Forecasts After Q4 Earnings

DexCom, Inc. DXCM reported weaker-than-expected earnings for its fourth quarter on Thursday.

5 weeks ago - Benzinga

DexCom, Inc. (DXCM) Q4 2024 Earnings Call Transcript

DexCom, Inc. (NASDAQ:DXCM) Q4 2024 Earnings Conference Call February 13, 2025 4:30 PM ET Company Participants Sean Christensen - Vice President of Finance and Investor Relations Kevin Sayer - Chairma...

5 weeks ago - Seeking Alpha

Dexcom beats fourth-quarter sales, reiterates 2025 revenue forecast

Medical device maker Dexcom beat fourth-quarter sales estimates helped by resilient demand for its continuous glucose monitors (CGMs) used by patients with diabetes.

5 weeks ago - Reuters

Dexcom Reports Fourth Quarter and Fiscal Year 2024 Financial Results

SAN DIEGO--(BUSINESS WIRE)--Dexcom Reports Fourth Quarter and Fiscal Year 2024 Financial Results.

5 weeks ago - Business Wire

Dexcom Schedules Fourth Quarter and Fiscal Year 2024 Earnings Release and Conference Call for February 13, 2025 at 4:30 p.m. Eastern Time.

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its fourth quarter and fiscal year 2024 financial results after market close on Thursday, February 13, 2...

7 weeks ago - Business Wire

DexCom: Fairly Priced In 2025; Why I'm Not Expecting A Share Price Comeback

DexCom, Inc.'s growth is impressive but limited by its niche market, with my projected ceiling being ~$7.5bn in peak annual revenues. Despite positive Q4 2024 results, DexCom's stock is fairly valued,...

2 months ago - Seeking Alpha

Healthy Returns: From Eli Lilly to Amazon, here are the latest health-care deals

Companies from Johnson & Johnson to Eli Lilly, Amazon and Nvidia are announcing health-related deals at the JPMorgan Health Care Conference.

2 months ago - CNBC

Dexcom forecasts 2025 revenue mostly in-line with expectations

Dexcom forecast total annual revenue in line with Wall Street expectations on Monday, on bets of strong demand for its continuous glucose monitors for diabetes patients.

2 months ago - Reuters

Dexcom Reports Preliminary, Unaudited Results for the Fourth Quarter and Fiscal Year 2024 and Initial 2025 Outlook

SAN DIEGO--(BUSINESS WIRE)--Dexcom Reports Preliminary, Unaudited Results for the Fourth Quarter and Fiscal Year 2024 and Initial 2025 Outlook.

2 months ago - Business Wire

Dexcom to Present at 43rd Annual J.P. Morgan Healthcare Conference

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the 43rd annual J.P. Morgan Healthcare Conference on January 13, 2025. T...

2 months ago - Business Wire

Digital health companies got pummeled by Wall Street in 2024 as industry adapts to post-Covid slowdown

It's been nearly five years since the coronavirus broke out in the U.S., but digital health companies are still reeling from the aftermath. According to a CNBC analysis of 39 public digital health com...

3 months ago - CNBC

DexCom, Abbott Agree to Settlement in Patent Litigation

The companies have been involved in global patent litigation, with both having accused the other of infringing certain patents, and each has filed counterclaims and actions to invalidate the other par...

Other symbols: ABT
3 months ago - WSJ

Abbott and DexCom settle glucose monitor patent disputes

Abbott Laboratories said on Monday it and DexCom have reached an agreement to settle all patent disputes between the companies related to continuous glucose monitoring devices.

Other symbols: ABT
3 months ago - Reuters

Diabetes Brands Dexcom, Ozempic, Mounjaro Drive Q3 Convergent TV Ad Engagement

NEW YORK--(BUSINESS WIRE)--EDO, the TV outcomes company, has released its Q3 2024 Diabetes Convergent TV Outcomes Report, providing critical insights into the diabetes category linear and streaming TV...

3 months ago - Business Wire

Dexcom's over-the-counter glucose monitor now offers users an AI summary of how sleep, meals and more impact sugar levels

Dexcom on Tuesday announced its first generative AI feature for its Stelo biosensor that gives users a personalized weekly report about their glucose. The company has been building a generative AI pla...

3 months ago - CNBC

Dexcom Launches the First Generative AI Platform in Glucose Biosensing

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today it has launched a proprietary Generative AI (GenAI) platform, making Dexcom the first C...

3 months ago - Business Wire